Loading viewer...
investor_presentation
Format: PDF investor_presentation
Investor RelationsMay 4, 2020Second Quarter Fiscal Year 2020
Investor RelationsMay 4, 2020Second Quarter
This presentation is intended exclusively for investors.
It is not intended for use in Sales or Marketing.
Forward -Looking Statements
Except forhistorical information, thispresentation contains forward -looking statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Statements concerning thecompany’s
long-term growth andvalue creation strategies, future orders, backlog, liquidity, capital allocation priorities andtheanticipated impact oftheCOVID -19pandemic onourbusiness ;andanystatements
using theterms “could,” “believe,” “expect,” “promising,” “outlook,” “should,” “well-positioned,” “will” orsimilar statements areforward -looking statements thatinvolve risks anduncertainties thatcould
cause thecompany’s actual results todiffer materially from those anticipated .Such risks anduncertainties include thefuture impact oftheCOVID -19pandemic onourbusiness, including butnot
limited to,theimpact onourworkforce, operations, supply chain, demand forourproducts andservices, andourfinancial results andcondition ;ourability tosuccessfully manage thechallenges
associated withtheCOVID -19pandemic ;ourability toachieve expected synergies from acquisitions ;risks associated withintegrating recent acquisitions ;global economic conditions andchanges to
trends forcancer treatment regionally ;currency exchange rates andtaxrates ;theimpact oftheTaxCuts andJobs Act;theimpact oftheAffordable Health Care forAmerica Act(including excise
taxes onmedical devices) andanyfurther healthcare reforms (including changes toMedicare andMedicaid), and/or changes inthird-party reimbursement levels ;recent andpotential future tariffs ora
global trade war;demand foranddelays indelivery ofthecompany’s products ;thecompany’s ability todevelop, commercialize anddeploy new products ;thecompany’s ability tomeet Food andDrug
Administration (FDA) andother regulatory requirements, regulations orprocedures ;changes inregulatory environments ;risks associated withthecompany providing financing fortheconstruction and
start-upoperations ofparticle therapy centers, challenges associated withcommercializing thecompany’s proton solutions business ;challenges topublic tender awards andthelossofsuch awards or
other orders ;theeffect ofadverse publicity ;thecompany’s reliance onsole orlimited -source suppliers ;thecompany’s ability tomaintain orincrease margins ;theimpact ofcompetitive products and
pricing ;thepotential loss ofkeydistributors orkeypersonnel ;challenges related toentering intonew business lines;andtheother risks listed from time totime inthecompany’s filings with the
Securities andExchange Commission, which bythisreference areincorporated herein .Foradditional information concerning factors thatcould cause actual results andevents todiffer materially from
those projected herein, please refer toourForm 10-Kfortheyear ended September 27,2019 andsubsequent Forms 8-Kand10-Qfiled withtheSecurities andExchange Commission .Thecompany
Preview truncated — download the full document for the complete content.
conference
27 Pages
investor_presentation
14 Pages
TerraForm Power
Kintara Therapeutics Investor Presentation — June 2022
investor_presentationinvestor_presentation
22 Pages
Kintara Therapeutics, Inc.